Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25761271 | 1.00 | PTGS1 (0.43) | PTGS1KCNH2SMN1; SMN2HSD17B10PSMB5 | |
| SCHEMBL22197926 | 1.00 | PTGS1 (0.43) | PTGS1KCNH2SMN1; SMN2HSD17B10PSMB5 | |
| SCHEMBL25515733 | 1.00 | PTGS1 (0.43) | PTGS1KCNH2SMN1; SMN2HSD17B10PSMB5 | |
| SCHEMBL24295732 | 1.00 | PTGS1 (0.43) | PTGS1KCNH2SMN1; SMN2HSD17B10PSMB5 | |
| SCHEMBL25515378 | 0.79 | PTGS1 (0.54) | PTGS1KCNH2VNN1 | |
| SCHEMBL22151100 | 0.78 | PTGS1 (0.53) | PTGS1KCNH2CYP2C19VNN1 | |
| SCHEMBL22151099 | 0.78 | PTGS1 (0.53) | PTGS1KCNH2CYP2C19VNN1 | |
| SCHEMBL22151097 | 0.78 | PTGS1 (0.53) | PTGS1KCNH2CYP2C19VNN1 | |
| SCHEMBL22170810 | 0.74 | PTGS1 (0.56) | PTGS1KCNH2CYP2C19VNN1 | |
| SCHEMBL25759733 | 0.74 | PTGS1 (0.56) | PTGS1KCNH2CYP2C19VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834391-B2 | Pantothenamide analogues | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2023-12-05 | — | — | US | disclosed |
| US-20230159437-A1 | PANTOTHENAMIDE ANALOGUES | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2023-05-25 | — | — | US | disclosed |
| US-11572336-B2 | Pantothenamide analogues | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2023-02-07 | — | — | US | disclosed |
| US-20220073450-A1 | PANTOTHENAMIDE ANALOGUES | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572336-B2 | Pantothenamide analogues | NAMPT, VKORC1, NME4 | PTGS1 991/4885KCNH2 3921/4885SMN1; SMN2 3224/4885 |
| US-20220073450-A1 | PANTOTHENAMIDE ANALOGUES | NAMPT, VKORC1, NME4 | PTGS1 991/4885KCNH2 3921/4885SMN1; SMN2 3224/4885 |
| US-11834391-B2 | Pantothenamide analogues | NAMPT, VKORC1, NME4 | PTGS1 991/4885KCNH2 3921/4885SMN1; SMN2 3224/4885 |
| US-20230159437-A1 | PANTOTHENAMIDE ANALOGUES | NAMPT, VKORC1, NME4 | PTGS1 991/4885KCNH2 3921/4885SMN1; SMN2 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.